In vitro, research conducted on HCC827, HCC827ER, and H1975 lung cancer cells using a combination treatment of siRNA STAT3 with erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor) revealed an association of erlotinib resistance with STAT3 activation [140]. The gene discussed is STAT3; the disease is lung carcinoma.